Head-To-Head Comparison: Repligen (NASDAQ:RGEN) vs. Abpro (NASDAQ:ABP)

Repligen (NASDAQ:RGEN) and Abpro (NASDAQ:ABP) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a summary of current ratings for Repligen and Abpro, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0	3	11	1	2.87
Abpro	1	1	0	0	1.50

Repligen presently has a consensus target price of $179.62, suggesting a potential upside of 12.22%. Abpro has a consensus target price of $120.00, suggesting a potential upside of 5,006.38%. Given Abpro’s higher possible upside, analysts clearly believe Abpro is more favorable than Repligen.

Volatility and Risk

Repligen has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Abpro has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500.

Profitability

This table compares Repligen and Abpro’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Repligen	0.25%	4.66%	3.28%
Abpro	N/A	N/A	-344.76%

Valuation and Earnings

This table compares Repligen and Abpro”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$634.44 million	14.20	-$25.51 million	$0.02	8,002.50
Abpro	$180,000.00	35.51	-$7.23 million	($4.23)	-0.56

Abpro has lower revenue, but higher earnings than Repligen. Abpro is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

97.6% of Repligen shares are owned by institutional investors. Comparatively, 23.3% of Abpro shares are owned by institutional investors. 1.2% of Repligen shares are owned by company insiders. Comparatively, 13.7% of Abpro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Repligen beats Abpro on 11 of the 15 factors compared between the two stocks.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

About Abpro

Abpro Holdings Inc. is a biotechnology company. The company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.